Vascular Biogenics is a clinical stage biopharmaceutical company committed to developing targeted medicines for difficult-to-treat medical conditions. Using its platform technologies, Co. has created a pipeline of therapeutics to address cancer and immune-inflammatory diseases. Co.'s product candidates are built off of its two platform technologies: Vascular Targeting System, a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology, an antibody-based technology able to inhibit monocyte migration for immune-inflammatory applications. Co. is evaluating its primary candidate, ofra-vec, in a registration-enabling trial in platinum resistant ovarian cancer. We show 8 historical shares outstanding datapoints in our coverage of VBLT's shares outstanding history.
Understanding the changing numbers of VBLT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VBLT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VBLT by allowing them to research VBLT shares outstanding history
as well as any other stock in our coverage universe. |
Free VBLT Email Alerts:
Video: Shares Outstanding Importance
